UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000023855 |
|---|---|
| Receipt number | R000026792 |
| Scientific Title | A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602) |
| Date of disclosure of the study information | 2016/12/01 |
| Last modified on | 2018/02/17 12:45:22 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602)
Acronym
Evaluation of the steroid premedication for cancer chemotherapy associated osteoporosis (ESPRESSO-02/HGCSG1602)
Scientific Title
A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602)
Scientific Title:Acronym
Evaluation of the steroid premedication for cancer chemotherapy associated osteoporosis (ESPRESSO-02/HGCSG1602)
Region
| Japan |
Condition
Condition
Gastrointestinal cancer: colorectal cancer, non-colorectal cancer (gastroesophageal, pancreatic, and biliary cancer)
Classification by specialty
| Gastroenterology | Hepato-biliary-pancreatic medicine | Hematology and clinical oncology |
| Adult |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy and safety of denosumab for preventing a bone mineral density reduction in gastrointestinal cancer patients receiving the short-term periodic steroid premedication.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Explanatory
Developmental phase
Not applicable
Assessment
Primary outcomes
To investigate the efficacy of denosumab for preventing a bone mineral density reduction 16 weeks after induction of chemotherapy.
Key secondary outcomes
The incidence of hypocalcemia and jawbone necrosis 16 weeks after initiation of chemotherapy.
The variation of bone turnover markers (serum BAP and NTX) 16 weeks after initiation of chemotherapy.
The serum levels of albumin, calcium(Ca), phosphorus, creatinine(Cr), alkaline phosphatase(ALP), fasting blood glucose, serum intact PTH, serum TSH, serum FT3, serum FT4, and HbA1c as well as urinary Ca and Cr measured on the indicated days: baseline, day 7, 14, 28, and 16 weeks.
Subgroup analysis for ECOG PS,Primary site, treatment schedule (weekly, biweekly, and triweekly), total amounts of steroids, and sex.
Newly bone fractures and bone metastasis
Safety
JOQOL and FRAX.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Historical
Stratification
NO
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
1
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
The dose of denosumab (Prolia) is 60mg administered as a single subcutaneous injection within a week before the induction of chemotherapy. All participants should receive adequate calcium and vitamin D supplementation.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 90 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
(1) Histologically confirmed adenocarcinoma in colorectal or non-colorectal cancers, including esophageal, gastric, pancreatic, and biliary cancer.
(2) A schedules of periodical intravenous steroid administration as premedication for prevention of chemotherapy-induced nausea and vomiting or allergic reaction that was weekly, biweekly, and triweekly, and in which >4-week steroid-free intervals were not allowed.
(3) At least 40 yo and less than 90 yo at the time of informed consent.
(4) In case with women, postmenopausal women only.
(5) Evaluable lesions, according to RECIST version 1.1 detected by CT scan or MRI.
(6) High risk patient with steroid induced secondary osteoporosis.
(7) Written informed consent to participate as a subject in this clinical study.
(8) No prior treatment for osteoporosis.
(9) The following bone marrow, liver, and kidney function parameters measured within 14 days prior to enrollment:
i) Neutrophil count: over 1500/uL
ii) Platelet count: over 75000/uL
iii) Hemoglobin: over 7.0 g/dL
iv) Total bilirubin: under 1.5 mg/dL
v) AST,ALT levels: under 100 U/L
vi) serum creatinine levels: < 1.5 mg/dL
vii) serum calcium levels: over 8.0 mg/dL
(10) ECOG PS of 0 to 1
(11) Life expectancy of at least 120 days after enrollment
(12) Already orally and/or dental care screening for eligibility has done.
Key exclusion criteria
(1) Current regular use of steroids.
(2) Current regular use of bisphosphonates or other drugs that affect the skeleton.
(3) Regimens with steroid free interval >4-weeks.
(4) Patients who cannot do the examination for DXA
(5) Past radiation therapy for the evaluation lesion of DXA
(6) Past total or partial gastrectomy
(7) Serum calcium levels < 8.0 mg/dL
(8) On going dental interventional treatment.
(9) Renal dysfunction (serum creatinine levels: over 1.5 mg/dL)
(10) Other concurrent active cancer (synchronous double cancer or heterochronous double cancer with a disease-free interval of 5 years or shorter,excluding colorectal cancer, lesions consistent with intraepithelial cancer, i.e., carcinoma in situ, or intramucosal cancer that are assessed as cured by local treatment).
(11) Premenopausal, pregnant, breast-feeding, possibly pregnant women or patients wishing to have children.
(12) Accumulation of pleural, ascitic, or pericardial fluid requiring drainage
(13) Active bleeding
(14) No prior operation for gastrointestinal tract within 28 day except proctostomy.
(15) Current or past severe lung disease (e.g. interstitial pneumonia, pulmonary fibrosis, or severe emphysema).
(16) Any other active illness such as severe cardiac disease (e.g. myocardial infarction, angina pectoris, arrhythmia, or cardiac failure). Any of the following events within the 6 months prior to enrollment.
(17) Serious hypersensitivity to any ingredients of denosumab.
(18) Active infection and/or inflammatory diseases.
(19) Severe cardiac failure (over NYHA II)
(20) Ineligible for participating in this study according to the investigator.
Target sample size
45
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Michio Nakamura |
Organization
Sapporo City General Hospital
Division name
Dept. of Gastroenterology
Zip code
Address
1-1, Kita 11 jo, Nishi 13 chome, Chuo-ku,Sapporo, Japan
TEL
+81-11-726-2211
michio.nakamura@doc.city.sapporo.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Michio Nakamura |
Organization
Sapporo City General Hospital
Division name
Dept. of Gastroenterology
Zip code
Address
1-1, Kita 11 jo, Nishi 13 chome, Chuo-ku,Sapporo, Japan
TEL
+81-11-726-2211
Homepage URL
michio.nakamura@doc.city.sapporo.jp
Sponsor or person
Institute
HGCSG (Hokkaido Gastrointestinal Cancer Study Group)
Institute
Department
Personal name
Funding Source
Organization
HGCSG (Hokkaido Gastrointestinal Cancer Study Group)
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
特定非営利活動法人 北海道消化器癌化学療法研究会（HGCSG）
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 12 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2016 | Year | 08 | Month | 05 | Day |
Date of IRB
Anticipated trial start date
| 2017 | Year | 02 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 08 | Month | 31 | Day |
Last modified on
| 2018 | Year | 02 | Month | 17 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026792
